Premium
P1‐267: Metabolic evidence of compensation for amyloid pathology in nondemented elderly individuals
Author(s) -
Mormino Elizabeth C.,
Hayenga Amynta O.,
Madison Cindee M.,
Kluth Jenny T.,
Furst Ansgar J.,
Rabinovici Gil D.,
Jagust William J.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.857
Subject(s) - precuneus , nuclear medicine , voxel , medicine , psychology , atrophy , pathology , neuroscience , radiology , cognition
0/2; MMSE: 29-30) participated in this study. Twice PET studies were performed on all subjects with an interval of 1.8 /0.4 years (mean /SD). All AD patients were treated with cholinesterase inhibitor at the time of second PET study, while all MCI patients had not been given any medicine. Two MCI patients had converted to AD at the time of second PET study and one of them had started to be treated with cholinesterase inhibitor. After intravenous injection of [11C]PIB (about 370 MBq), a dynamic PET scan was performed for 90min with arterial blood sampling. All PET images were normalized to the MNI space using SPM. Distribution volume ratios (DVR), indicating the retention of [11C]PIB, were calculated on a voxel-by-voxel basis by Logan graphical analysis with the use of cerebellum as a reference brain region. Regions of interest (ROI) were drawn on the DVR images. Results: Increase in DVR of [11C]PIB of 27-43% in the cerebral cortex during interval period of two PET studies was observed in two MCI patients who had converted to AD at the time of second PET study. The change in DVR was within 6% in the cerebral cortex during period in two AD patients, two MCI patients who had remained MCI at second study, and two controls. Conclusions: Increase in beta-amyloid deposition during 2 years was shown in MCI patients who converted to AD. MCI patients showing progression of beta-amyloid accumulation in the brain may be the best candidates for amyloid modulating therapy.